Login    Join free Add to favorites    中文
home > news > AYOXXA launches LUNARISTM Mouse 12-Plex Th17 Kit
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
AYOXXA launches LUNARISTM Mouse 12-Plex Th17 Kit

hits:1536     Date:09/18/17
AYOXXA launches LUNARISTM Mouse 12-Plex Th17 Kit to elucidate Th17 cell biology
  • LUNARISTM Mouse 12-Plex Th17 Kit comprises highly specific reagents for the quantitative analysis of soluble markers of Th17 cell biology
  • Kit includes the primary Th17 related cytokines involved in autoimmune disorders, immune-mediated diseases as well as asthma, allergy, cancer, microbial defense and transplantation 
  • Launch marks a further step in establishing AYOXXA's LUNARISTM as the technology of choice for fully scalable beads-on-a-chip multiplex protein analysis allowing minimal sample volumes for maximal results
  • LUNARISTM Mouse 12-Plex Th17 Kit is available as of September 2017
Cologne, Germany, September 18, 2017 - AYOXXA Biosystems GmbH, an international biotechnology company, focused on the development of innovative multiplex protein analysis technologies enabling translational research in basic and clinical research, today announced the expansion of its catalogue of immunoassays for multiplex protein analysis with the introduction of LUNARISTM Mouse 12-Plex Th17 Kit for the quantitative analysis of soluble mouse T helper 17 (Th17) cell-related markers. The assay is optimized for usage on LUNARISTM, AYOXXA's innovative multiplex protein analysis system.
"Providing tools to enable translational research is our primary mission. In expanding our portfolio of multiplex panels, we take our cue from users of our system who are looking for new and better tools for accurate and precise quantitative protein analysis," said Rodney Turner, CEO of AYOXXA. "The LUNARISTM Mouse 12-Plex Th17 Kit represents the latest disease related panel we have added to our growing menu of kits. The opportunity to simultaneously analyze multiple cytokines related to Th17 in very small samples will specifically support researchers studying murine models of Th17 biology. We are confident that this kit, and related products in our pipeline, will enable scientists in the development of novel treatments in Th17 related diseases."
The new LUNARISTM Mouse 12-Plex Th17 Kit comprises a panel of highly specific antibody pairs against CCL20, IFN-γ, IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17E, IL-17F, IL-21, IL-23 and TGF-β1. These cytokines are involved in regulating the differentiation and effector functions of Th17 cells in different pathogenic conditions including autoimmune disorders, immune-mediated diseases as well as asthma, allergy, cancer, microbial defense and transplantation
Particularly noteworthy is the opportunity to measure the active form of "transforming growth factor beta 1" (TGF-β1) which is missing in most comparable assays. The absence or presence of TGF-β1, in combination with other cytokines such as IL-1β, IL-6 or IL-23, which are also covered by this assay, regulates the differentiation of Th17 cells and is thereby important for the final outcome and character (anti-infective or pathogenic) of immune responses.
The LUNARISTM Mouse 12-Plex Th17 Kit is optimized to run on AYOXXA's proprietary multiplex protein analysis system LUNARISTM, an automated system that can be readily integrated into any laboratory routine and is optimized to provide an easy-to-use, standardized workflow from sample to result. It combines the familiarity of standard immunoassay workflow with unmatched capability for low sample volume, scalability for low- to high-throughput applications and market leading data quality. The system comprises a dedicated LUNARISTM reader and best-in-class automated analysis software for image-based analysis with a 100% read-out.
LUNARISTM assays follow a classical sandwich immunoassay principle with fluorescence readout. The BioChips are painstakingly optimized using the best quality antibody-pairs to ensure the highest assay sensitivity and specificity with minimal cross-reactivity in a multiplex format. Due to the innovative BioChip setup and geometry, LUNARISTMassays can be performed with sample volumes as low as 3µL - which represents only 1/10 of the volume required by comparable multiplex technologies. This low minimum volume requirement enables multiplex protein analysis from valuable and scarce human and animal samples.
"The superior features in terms of data quality, minimal sample volume requirements and scalability make the LUNARISTM system an ideal choice for state of the art biomarker screening and validation. This provides AYOXXA with clear competitive advantages in the rapidly growing field of multiplex protein analysis in translational science. The growing portfolio of disease related panels like the new LUNARISTM Mouse 12-Plex Th17 Kit fuels the understanding of underlying biological mechanisms. The robustness of the LUNARISTM system evaluated in numerous clinical partnerships will drive the transfer of this knowledge generated in a laboratory through the entire drug development process," said Wolfgang Kintzel, COO of AYOXXA.
The new LUNARISTM Mouse 12-Plex Th17 Kit adds to the already existing portfolio of standardized biomarker kits including human and mouse cytokine as well as ophthalmology panels. The newly introduced LUNARISTM Mouse 12-Plex Th17 Kit is available as of September 2017.
For more information on the LUNARISTM Mouse 12-Plex Th17 Kit please visit www.ayoxxa.com/newsroom
About Th17 cells:
The dysregulation of the balance of Th17 cells and other immune cells has been associated with a variety of pathogenic conditions including rheumatoid arthritis, psoriasis and multiple sclerosis. Th17 cells can be broadly divided into two groups, the host protective cells that express both IL-17A and IL-17F and IL-10 and the highly inflammatory population which expresses IL-17A, IL-17F, IL-22 and IFN-γ. Th17 cells activated by transforming growth factor-β1 (TGF-β1) and IL-6 promote mucosal defense, barrier tissue integrity and curtails immunopathogenic responses, whereas IL-1β and IL-23-activated Th17 cells have been shown to cause chronic tissue inflammation during infection, granuloma formation and autoimmune response.
AYOXXA Biosystems GmbH is an international life science company based in Cologne (Germany) with offices in Boston, MA (USA) and Singapore. AYOXXA enables its customers and partners to utilize its reliable and optimized platform technology to fuel breakthroughs in all areas of life science research and to enhance success in translational science.
With LUNARISTM, its proprietary innovative beads-on-a-chip multiplexing platform for advanced protein analysis, the Company is paving the way for translating knowledge generated in a laboratory environment through clinical studies in support of basic biology and across drug development. With its advantages in terms of quality, flexibility, robustness and efficiency, LUNARISTM enables fully scalable quantitative validation of biomarkers in minute amounts of biological samples. AYOXXA is commercializing a growing portfolio of standardized ready-to-use biomarker analysis assays, with a focus on the biology of inflammation and immune response.
Related News>> more

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   沪ICP备06040519号